Details
Stereochemistry | ACHIRAL |
Molecular Formula | C9H23NO3PS.I |
Molecular Weight | 383.227 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
[I-].CCOP(=O)(OCC)SCC[N+](C)(C)C
InChI
InChIKey=OVXQHPWHMXOFRD-UHFFFAOYSA-M
InChI=1S/C9H23NO3PS.HI/c1-6-12-14(11,13-7-2)15-9-8-10(3,4)5;/h6-9H2,1-5H3;1H/q+1;/p-1
Molecular Formula | C9H23NO3PS |
Molecular Weight | 256.323 |
Charge | 1 |
Count |
|
Stereochemistry | RACEMIC |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
Molecular Formula | HI |
Molecular Weight | 127.9124 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
Echothiophate is a potent, long-acting irreversible cholinesterase inhibitor used as an ocular hypertensive in the treatment of glaucoma. Occasionally used for accomodative esotropia. Echothiophate iodide for ophthalmic solution will depress both plasma and erythrocyte cholinesterase levels in most patients after a few weeks of eye drop therapy by binding irreversibly to cholinesterase, and thus long acting due to the slow rate of hydrolysis by cholinesterase. It causes miosis, increase in facility of outflow of aqueous humor, fall in intraocular pressure, and potentiation of accommodation.
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL2095233 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Palliative | PHOSPHOLINE IODIDE Approved UseGlaucoma Chronic open-angle glaucoma. Subacute or chronic angle-closure glaucoma after iridectomy or where surgery is refused or contraindicated. Certain non-uveitic secondary types of glaucoma, especially glaucoma following cataract surgery. Accommodative Esotropia Concomitant esotropias with a significant accommodative component. Launch Date-3.00240011E11 |
|||
Palliative | PHOSPHOLINE IODIDE Approved UseGlaucoma Chronic open-angle glaucoma. Subacute or chronic angle-closure glaucoma after iridectomy or where surgery is refused or contraindicated. Certain non-uveitic secondary types of glaucoma, especially glaucoma following cataract surgery. Accommodative Esotropia Concomitant esotropias with a significant accommodative component. Launch Date-3.00240011E11 |
PubMed
Title | Date | PubMed |
---|---|---|
Echothiophate iodide: its use in accommodative esotropia (high Ac/A ratio). | 1982 Jul |
|
DNA sequence of butyrylcholinesterase from the rat: expression of the protein and characterization of the properties of rat butyrylcholinesterase. | 2002 Jun 15 |
|
The effect of fluoride on the scavenging of organophosphates by human butyrylcholinesterase in buffer solutions and human plasma. | 2004 Jan 1 |
|
Role of water in aging of human butyrylcholinesterase inhibited by echothiophate: the crystal structure suggests two alternative mechanisms of aging. | 2005 Feb 1 |
|
Butyrylcholinesterase, paraoxonase, and albumin esterase, but not carboxylesterase, are present in human plasma. | 2005 Nov 25 |
|
Aging pathways for organophosphate-inhibited human butyrylcholinesterase, including novel pathways for isomalathion, resolved by mass spectrometry. | 2007 Nov |
|
In silico modeling of the specific inhibitory potential of thiophene-2,3-dihydro-1,5-benzothiazepine against BChE in the formation of beta-amyloid plaques associated with Alzheimer's disease. | 2010 Jun 16 |
Patents
Sample Use Guides
Early Chronic Simple Glaucoma: echothiophate iodide for ophthalmic solution 0.03% instilled twice a day, just before retiring and in the morning, may be prescribed advantageously for cases of early chronic simple glaucoma that are not controlled around-the-clock with other less potent agents. Because of prolonged action, control during the night and early morning hours may then sometimes be obtained. A change in therapy is indicated if, at any time, the tension fails to remain at an acceptable level on this regimen.
Advanced Chronic Simple Glaucoma and Glaucoma Secondary to Cataract Surgery: these cases may respond satisfactorily to echothiophate iodide for ophthalmic solution 0.03% twice a day as above. When the patient is being transferred to echothiophate iodide for ophthalmic solution because of unsatisfactory control with pilocarpine, carbachol, epinephrine, etc., one of the higher strengths, 0.06%, 0.125%, or 0.25% will usually be needed. In this case, a brief trial with the 0.03% eyedrops will be advantageous in that the higher strengths will then be more easily tolerated.
Concomitant Therapy: echothiophate iodide for ophthalmic solution may be used concomitantly with epinephrine, a carbonic anhydrase inhibitor, or both. Technique – Good technique in the administration of echothiophate iodide for ophthalmic solution requires that finger pressure at the inner canthus should be exerted for a minute or two following instillation of the eyedrops, to minimize drainage into the nose and throat. Excess solution around the eye should be removed with tissue and any medication on the hands should be rinsed off.
Accommodative Esotropia (Pediatric Use) In Diagnosis: one drop of 0.125% may be instilled once a day in both eyes on retiring, for a period of two or three weeks. If the esotropia is accommodative, a favorable response will usually be noted which may begin within a few hours. In Treatment – Echothiophate iodide for ophthalmic solution is prescribed at the lowest concentration and frequency which gives satisfactory results. After the initial period of treatment for diagnostic purposes, the schedule may be reduced to 0.125% every other day or 0.06% every day. These dosages can often be gradually lowered as treatment progresses. The 0.03% strength has proven to be effective in some cases. The maximum usually recommended dosage is 0.125% once a day, although more intensive therapy has been used for short periods.
Route of Administration:
Other
Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 15:54:33 UTC 2023
by
admin
on
Sat Dec 16 15:54:33 UTC 2023
|
Record UNII |
BA9QH3P00T
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Official Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C47792
Created by
admin on Sat Dec 16 15:54:33 UTC 2023 , Edited by admin on Sat Dec 16 15:54:33 UTC 2023
|
||
|
FDA ORPHAN DRUG |
871422
Created by
admin on Sat Dec 16 15:54:33 UTC 2023 , Edited by admin on Sat Dec 16 15:54:33 UTC 2023
|
||
|
EU-Orphan Drug |
EU/3/15/1474
Created by
admin on Sat Dec 16 15:54:33 UTC 2023 , Edited by admin on Sat Dec 16 15:54:33 UTC 2023
|
||
|
FDA ORPHAN DRUG |
430914
Created by
admin on Sat Dec 16 15:54:33 UTC 2023 , Edited by admin on Sat Dec 16 15:54:33 UTC 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
DBSALT001098
Created by
admin on Sat Dec 16 15:54:33 UTC 2023 , Edited by admin on Sat Dec 16 15:54:33 UTC 2023
|
PRIMARY | |||
|
208-152-1
Created by
admin on Sat Dec 16 15:54:33 UTC 2023 , Edited by admin on Sat Dec 16 15:54:33 UTC 2023
|
PRIMARY | |||
|
100000080508
Created by
admin on Sat Dec 16 15:54:33 UTC 2023 , Edited by admin on Sat Dec 16 15:54:33 UTC 2023
|
PRIMARY | |||
|
C47505
Created by
admin on Sat Dec 16 15:54:33 UTC 2023 , Edited by admin on Sat Dec 16 15:54:33 UTC 2023
|
PRIMARY | |||
|
BA9QH3P00T
Created by
admin on Sat Dec 16 15:54:33 UTC 2023 , Edited by admin on Sat Dec 16 15:54:33 UTC 2023
|
PRIMARY | |||
|
CHEMBL1201341
Created by
admin on Sat Dec 16 15:54:33 UTC 2023 , Edited by admin on Sat Dec 16 15:54:33 UTC 2023
|
PRIMARY | |||
|
513-10-0
Created by
admin on Sat Dec 16 15:54:33 UTC 2023 , Edited by admin on Sat Dec 16 15:54:33 UTC 2023
|
PRIMARY | |||
|
BA9QH3P00T
Created by
admin on Sat Dec 16 15:54:33 UTC 2023 , Edited by admin on Sat Dec 16 15:54:33 UTC 2023
|
PRIMARY | |||
|
10547
Created by
admin on Sat Dec 16 15:54:33 UTC 2023 , Edited by admin on Sat Dec 16 15:54:33 UTC 2023
|
PRIMARY | |||
|
D004456
Created by
admin on Sat Dec 16 15:54:33 UTC 2023 , Edited by admin on Sat Dec 16 15:54:33 UTC 2023
|
PRIMARY | |||
|
m4818
Created by
admin on Sat Dec 16 15:54:33 UTC 2023 , Edited by admin on Sat Dec 16 15:54:33 UTC 2023
|
PRIMARY | Merck Index | ||
|
3740
Created by
admin on Sat Dec 16 15:54:33 UTC 2023 , Edited by admin on Sat Dec 16 15:54:33 UTC 2023
|
PRIMARY | RxNorm | ||
|
59849
Created by
admin on Sat Dec 16 15:54:33 UTC 2023 , Edited by admin on Sat Dec 16 15:54:33 UTC 2023
|
PRIMARY | |||
|
SUB06451MIG
Created by
admin on Sat Dec 16 15:54:33 UTC 2023 , Edited by admin on Sat Dec 16 15:54:33 UTC 2023
|
PRIMARY | |||
|
DTXSID1022976
Created by
admin on Sat Dec 16 15:54:33 UTC 2023 , Edited by admin on Sat Dec 16 15:54:33 UTC 2023
|
PRIMARY | |||
|
662
Created by
admin on Sat Dec 16 15:54:33 UTC 2023 , Edited by admin on Sat Dec 16 15:54:33 UTC 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
PARENT -> SALT/SOLVATE |
|
||
|
TARGET -> INHIBITOR |
IRREVERSIBLE INHIBITOR
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |
|